Delivery Order SPE2DR25D3103-SPE2DR26F9H37
- Not listed
- The Defense Logistics Agency (DLA) awarded a $9,374.36 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on April 22, 2025, with completion scheduled for May 13, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a $46.9K delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The order will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of October 6, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The delivery order is issued under...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The products will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $7,409.34 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors on November 13, 2025, with completion expected by December 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is not set-aside and competitively awarded, has an ultimate completion date of November 19, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $14,818.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectables on November 12, 2025, with completion targeted for December 4, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and reflects...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency has awarded a delivery order valued at $4,939.58 to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 mL pen injectors. This is a firm fixed price, competitively awarded contract with an ultimate completion date of November 28, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a larger contract vehicle, this award leverages AmerisourceBergen's...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9H37Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,879.12 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of December 12, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including critical medications, vaccines, and medical devices across multiple therapeutic domains. Tezspire is a specialty biologic medication used in the treatment of severe asthma, representing the type of specialized pharmaceutical commodity that DLA procures to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.9k | 11/20/25 |